Table 1.
Activity of CV-N against patient isolates of SARS-CoV-2 in plaque reduction assays
| SARS-CoV-2 isolate | Pango variant* | WHO variant† | IC50 (95% CI‡, [nM]) | IC90 [nM] |
|---|---|---|---|---|
| SP1 | B | – | 8.353 (6.753-10.33) | 109.65 |
| RJ1 | A.2 | – | 9.937 (8.177-12.08) | 114.82 |
| RJ2 | B.1.1.33 | – | 14.86 (10.85-20.36) | 158.49 |
| 4117 | B.1.1.33 | – | 89.77 (76.85-104.9) | 549.54 |
| 6439 | B.1.1.33 | – | 13.03 (9.246-18.36) | 269.15 |
| 814 | P.2 | Zeta | 6.685 (4.836-9.241) | 208.93 |
| P1USP | P.1 | Gamma | 33.76 (27.56-41.36) | 218.78 |
| 49947 | B.1.617.2 | Delta | 7.291(4.914-10.82) | 109.65 |
| OmiSP | B.1.1.529 | Omicron | 0.674 (0.5271-0.8607) | 6.46 |
*Data generated by https://pangolin.cog-uk.io/.
†Nomenclature stated by World Health Organization, https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
‡95% CI of CV-N IC50 estimation.